Rituximab therapy
Rituximab therapy reduces activated B cells in both the peripheral blood and bone marrow of patients with rheumatoid arthritis: depletion of memory B cells correlates with clinical response
... after rituximab therapy - synovial B cells decreased but were not eliminated ...received rituximab, PB B cells were depleted at 4 weeks whereas synovial B cells were only moderately reduced and ...
8
Circulating microRNAs as biomarkers for rituximab therapy, in neuromyelitis optica (NMO)
... Several attempts have been made to develop bio- markers in order to individualize rituximab therapy in NMO patients. CD19+ and CD27 + CD19 + B cell counts were studied by Kim et al. in NMO patients treated ...
8
Effectiveness of Rituximab Therapy on Severe Calcinosis in 4 Children with Juvenile Dermatomyositis
... of rituximab on severe calcinosis in 4 JDM patients and present their clinical ...received rituximab for relapsing or polycyclic JDM ...about rituximab therapy included: dosage, side effects, ...
14
Severe Ulcerative Colitis After Rituximab Therapy
... after rituximab therapy in a child with refractory, steroid- dependent ...NS. Rituximab therapy led to complete depletion of peripheral and intestinal CD19 ⫹ and CD20 ⫹ B ...possibly ...
6
Metabolomic profiling predicts outcome of rituximab therapy in rheumatoid arthritis
... to rituximab administration, 24 metabolites achieved ...following rituximab therapy, there were greater differences between responders and non-responders, with 43 signi fi cant metabolites, likely due ...
9
Case Report Bone marrow infiltration of CD20-negative follicular lymphoma after rituximab therapy: a histological mimicker of hematogones and B-cell acute lymphoblastic leukemia/lymphoma
... with rituximab, followed by rituximab ma- intenance, which was considered to be partially effective: on admission to our hospital at this time, his serum biochemistry showed decrease in lactate ...
5
The effect of rituximab therapy on immunoglobulin levels in patients with multisystem autoimmune disease
... before rituximab); 2/3 patients had moderate hypogammaglobulinaemia including the patient with chronic aspergillosis who required IVIg replacement; two had infection with herpes zoster, one with moderate ...
9
Original Article Rituximab therapy and increased risk of side effects in patients with relapsed lymphomas: a meta-analysis
... maintenance therapy after autol- ogous stem-cell transplantation (ASCT) shows a slightly higher AE rate than the observation only after ASCT (47% ...maintenance therapy with R for the relapsed FL, compared ...
11
Rituximab Is Indispensable for Pediatric Heart Transplant Recipients Developing Post transplant Lymphoproliferative Disorders
... rituximab therapy. Moreover, the very excellent outcome achieved by rituximab therapy in pediatric recipients of heart allograft with PTLD leaves rituximab a compelling agent in the ...
10
Rituximab-Induced Bronchiolitis Obliterans Organizing Pneumonia
... with a rituximab-containing regimen. Among these patients, 9 (8%) developed interstitial pneumonitis during rituximab therapy [12], suggesting a higher incidence of R-ILD than previously considered. ...
5
Severe refractory autoimmune hemolytic anemia with both warm and cold autoantibodies that responded completely to a single cycle of rituximab: a case report
... transfusion-independent and his last hemoglobin level was 12.5 g/dL. Another renal biopsy was performed and demonstrated nodular mesangial widening with increased matrix and tubular basement membrane thickening with- out ...
5
Reversible rituximab-induced rectal Kaposi’s sarcoma misdiagnosed as ulcerative colitis in a patient with HIV-negative follicular lymphoma
... under rituximab treatment in a HIV‑ negative 55‑year‑old patient treated for follicular ...maintenance rituximab therapy at the rectal level with an aspect of apparent ulcerative colitis, without any ...
8
Intravascular CNS lymphoma: Successful therapy using high-dose methotrexate-based polychemotherapy
... Intravascular diffuse large B-cell lymphoma limited to the CNS (cIVL) is a very rare malignant disorder characterized by a selective accumulation of neoplastic lymphocytes (usually B cells) within the lumen of CNS blood ...
5
Setting the target for pemphigus vulgaris therapy
... after rituximab therapy can be explained by incomplete B cell depletion in bone marrow and secondary lymphoid organs (a known limitation of rituximab efficacy; ...by rituximab, then strategies ...
12
PEMPHIGUS VULGARIS: AN INSIGHT ON CONVENTIONAL AND EMERGING TREATMENT MODALITIES
... pulse therapy, immunoablative therapy with cyclophosphamide, plasmapheresis, extracorporeal photochemotherapy, intravenous immunoglobulin (IVIg) therapy, and, most recently, anti-CD20 chimeric ...
5
Current perspective on rituximab in rheumatic diseases
... treatments, rituximab (RTX), first used in the treatment of non-Hodgkin’s lymphoma, was later approved for rheumatoid arthritis and anti-neutrophil cytoplasmic antibodies-associated ...
14
Eosinophilic Granulomatosis with Polyangiitis: Experiences in Korean Patients
... cebo-controlled, double-blind, parallel-group clinical trial in- vestigating the efficacy and safety of mepolizumab in relapsing or refractory EGPA have been reported. Mepolizumab (300 mg subcutaneous every 4 weeks) ...
8
Progressive dyspnoea following the treatment of Mycobacterium abscessus infection in an individual with relapsing granulamatosis with polyangitis (Wegener’s), complicated by hearing loss requiring cochlear implantation
... cycophosphamide 1.5 mg/kg. On this occasion, he was not treated with MESNA and after 2 months of treat- ment, developed hemorrhagic cystitis. His treatment was then changed to rituximab 375 mg/m 2 weekly for 4 ...
5
6217.pdf
... . However, these studies do not directly address the impact on Tregs in ANCA disease patients. In conjunction with these studies, the potential “fluctuation” between full-length and exon 2- deficient FOXP3 over time is ...
109
Interleukin-6 inhibition for treatment of rheumatoid arthritis: A review of tocilizumab therapy
... Canada, and Israel), randomized, double-blind, double- dummy, placebo-group study evaluating the efficacy and safety of TCZ monotherapy versus MTX in patients with active RA for whom previous therapy with MTX and/ ...
16